MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers

News | 04. 16. 2008

Mirati Therapeutics

MGCD265 Targets c-Met, VEGFs, Tie-2 and Ron Receptor Tyrosine Kinases

Initial Compound from Portfolio of Potent Multi-targeted Kinase Inhibitors

Montreal, Quebec. April 16, 2008 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data for MGCD265, an oral, multi-targeted (c-Met) kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.